Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

3374 - New approach to gastric cancer classification based on TP53 mutation


08 Oct 2016


Poster Display


Rie Makuuchi


Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371


R. Makuuchi1, K. Hatakeyama2, M. Terashima1, M. Kusuhara2, M. Tokunaga1, Y. Tanizawa1, E. Bando1, T. Kawamura1, M. Hikage1, S. Kaji1, K. Ohshima2, K. Urakami2, K. Yamaguchi2

Author affiliations

  • 1 Gastric Surgery, Shizuoka Cancer Center, 4110942 - Shizuoka/JP
  • 2 Research Institute, Shizuoka Cancer Center, 4110942 - Shizuoka/JP


Abstract 3374


Recently, novel classifications based on molecular profiling have been advocated for various solid tumors. In gastric cancer, the Cancer Genome Atlas and the Asian Cancer Research Group (ACRG) have proposed a new classifications using genomic alterations. We previously reported that the ACRG classification was also applicable to Japanese patients. However, there was no difference of survival depending on TP53 activation signature, though progress between tumors of microsatellite instability (MSI) and epithelial-mesenchymal transition (EMT) was obviously different. The aim of this study is to propose a new classification which clearly categorize gastric cancer using TP53 tumor specific single nucleotide mutation.


We have launched a comprehensive molecular profiling in project HOPE (High-tech Omics-based Patient Evaluation) that analyzes genomes and transcriptomes of tumors obtained from the cancer patients admitted to Shizuoka Cancer Center from January 2014. Surgically-resected fresh tumor samples were analyzed by whole-exome sequencing (Ion Proton) and gene expression profiling (DNA microarray). A total of 188 patients with gastric cancer were included in this study. The patients were first subgrouped into MSI and EMT based on the ACRG classification. The remaining patients were then subgrouped by TP53 mutation status which depress its function (TP53+ and TP53-). Clinicopathological features and survival outcomes were compared among the groups.


The number of patients classified into the MSI, EMT, TP53 + , and TP53- group was 21, 22, 15 and 130, respectively. The median follow-up period was 349 days. The patients were significantly younger in EMT. The undifferentiated type was significantly dominant in MSI. There was no statistically significant difference in tumor depth, lymph node metastasis, or tumor stage among the groups. Two-year cause-specific survival (CSS) rates were 95.5% in MSI, 49.9% in EMT, 65.5% in TP53 + , and 78.5% in TP53- (p = 0.048). Although the follow-up period was insufficient, CSS was worse in TP53+ than in TP53-.


Using a modified version of the ARGC classification focusing on TP53 mutation, we found that selected TP53 mutations is a potential factor to define the genotype of gastric cancer as well as MSI and EMT.

Clinical trial identification

Legal entity responsible for the study

Shizuoka Cancer Center


Shizuoka Cancer Center


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings